Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR1E | P28566 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | HTR5A | P47898 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4099405 | 0.78 | HTR2A (0.35) | HTR2A | |
| SCHEMBL4090920 | 0.70 | KDM4E (0.36) | HTR1BHTR7 | |
| SCHEMBL5242696 | 0.66 | HTR1B (0.41) | HTR1BHTR7 | |
| SCHEMBL5421908 | 0.65 | CYP2A6 (0.38) | — | |
| SCHEMBL4040257 | 0.64 | AHR (0.33) | — | |
| SCHEMBL5430878 | 0.62 | — | — | |
| SCHEMBL4035177 | 0.62 | HRH3 (0.36) | HTR1B | |
| SCHEMBL5418310 | 0.62 | CYP2A6 (0.41) | — | |
| SCHEMBL5245117 | 0.61 | KDM4E (0.47) | — | |
| SCHEMBL4046122 | 0.61 | CACNA1B (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221687-A1 | Tetracyclic Monoamine Reuptake Inhibitors for Treatment of Cns Diseases and Disorders | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB (HR) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221687-A1 | Tetracyclic Monoamine Reuptake Inhibitors for Treatment of Cns Diseases and Disorders | MAOB, MAOA, TPH1 | HTR1A 11/4885HTR1D 42/4885HTR1B 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.